Study Questions And Answers For Nr 546 Questions With 100% Correct And Verified Answers. A+ Graded.

ll




STUDY QUESTIONS AND ANSWERS FOR NR 546
ll ll ll ll ll ll ll



QUESTIONS WITH 100%
ll ll ll



CORRECT AND VERIFIED
ll ll ll



ANSWERS. A+ GRADED.
ll ll ll

ll
ll
ll
ll
ll
ll
ll

Prefrontal llCortex ll Symptoms ll of MDD
ll -
ll ll CORRECT ll ANSWER-
Concentration
ll
Mental
llFatigue
ll
Mood
ll

PFC ll& llAmygdala llSymptoms llof llMDD ll- llCORRECT llANSWER-
Guilt
ll
Suicidality
ll
Worthlessness
ll

Striatum llSymptoms llof llMDD ll- llCORRECT llANSWER-Physical llfatigue ll
ll

Nucleus llAccumbens llSymptoms llof llMDD ll- llCORRECT llANSWER-Pleasure llinterests ll
ll

Hypothalamus llSymptoms llof llMDD ll- llCORRECT llANSWER-
Sleep
ll
Appetite
ll

Thalamus ll& llHypothalamus llSymptoms llof llMania ll- llCORRECT llANSWER-
Decreased ll
ll
sleep/arousal
ll

Striatum llSymptoms llof llMania ll- llCORRECT llANSWER-Motor/agitation ll
ll

Prefrontal llcortex ll(PFC) llSymptoms llof llMania ll- llCORRECT llANSWER-Risk-
taking
ll
Talkative/pressured llspeech
ll

Nucleus llAccumbens ll& llPFC llSymptoms llof llMania ll- llCORRECT llANSWER-
Racing ll
ll
thoughts,
llgrandiosity
ll

PFC ll& llAmygdala llSymptoms llof llMania ll- llCORRECT llANSWER-Mood ll
ll

,Medication llManagement ll- llCORRECT llANSWER-SSRI-Selective ll Serotonin
llReuptake ll
ll
Inhibitors
ll
*Inhibit ll5 llHT

llreuptake
ll ll
SNRI-Serotonin llNorepinephrine llReuptake

llInhibitors
ll
*inhibit ll5-HT

llreuptake
ll
*inhibit llNE llreuptake ll(increase llenergy,
llfocus)

*increase llDA llin llprefrontal llcortex ll(increase llcognition) ll
NDRI-Norepinephrine llDopamine llReuptake llinhibitors ll
*inhibit llDA llreuptake ll(increase llalertness, llmotivation) ll
*inhibit llNE llreuptake ll(increase llenergy) ll
SARI-Serotonin llAntagonist llReuptake llInhibitors ll
ll

Selective llSerotonin llReuptake llInhibitors ll(SSRIs): llMost lladverse lleffects llwill llsubside
llafter ll4-5 lldays llonce llthe llbody lladjusts llto llincreased llserotonin lllevels. ll- llCORRECT

llANSWERdiarrhea llheadache llweight llgain ll

sexual llside lleffects ll
ll

Serotonin llNorepinephrine llReuptake llInhibitors ll(SNRIs): llMedications llshould llnot llbe
llabruptly llstopped llto llavoid lldiscontinuation llsymptoms. llNE lleffects llof llthe llmedication

llmay llincrease llanxiety llin llsome llclients. llReport llworsening llanxiety llto llthe llprovider. ll-

llCORRECT ll

ANSWER-elevated llblood llpressure ll
anxiety
llinsomnia ll

constipation ll
ll

Norepinephrine llDopamine llReuptake llInhibitors ll(NDRI): llTake llmedication llin llthe
llmorning. ll

Stop lltaking llmedication llif llseizures lloccur. llStop lltaking llmedication llif llanxiety llis llnoted. ll-
ll

CORRECT llANSWER-agitation ll
headache
lldry llmouth

llconstipation ll

weight llloss ll
ll

escitalopram ll(Lexapro) ll SSRI ll - ll CORRECT ll ANSWER-no ll known ll drug
llinteractions
ll
best lltolerated


llSSRI

, ll
27-32 llhour llhalf-life llgood llfor llforgetful llprone
llclients
ll
least llCYP

llreactions
ll
Substrate llfor

ll3A4
ll

citalopram ll(Celexa) llSSRI ll- llCORRECT llANSWER-mild llantihistamine lleffects; llHalf-
Life: ll
ll
23-45
llhours
ll
Weak llInhibitor llof
ll2D6
ll

fluoxetine ll(Prozac) llSSRI ll- llCORRECT llANSWER-longest llhalf-life ll
Use llcaution llin llpatients llwith llcomorbid llanxiety lldue llto llrisk llfor llactivation lland llpanic
llattacks ll

Half-Life: ll2-3 lldays llparent, ll2 llweek llmetabolite ll
Inhibits ll2D6 lland ll3A4 ll
ll

paroxetine ll(Paxil) llSSRI ll- llCORRECT llANSWER-also lltreats llsocial llanxiety lland
llinsomnia
ll
associated llwith llweight
llgain


will llexperience llwithdrawal llwith llmissed lldose llor llabrupt
llstop
ll
Half-Life: ll24

llhours
ll
Inhibits
ll2D6
ll

fluvoxamine ll(Luvox) llSSRI ll- llCORRECT llANSWER-treats llanxious lldepression
llsmokers llrequire llan llincreased lldose llHalf-Life: ll9-28 llhours ll

Inhibits ll3A4, ll2C9, ll1A2 ll
ll

sertraline ll(Zoloft) llSSRI ll- llCORRECT llANSWER-also lltreats llsocial llanxiety
lland ll
ll
hypersomnolence
ll
Half-Life: ll22-36 llhour llparent; ll62-104 llhour
llmetabolite
ll
Inhibits ll2D6 lland ll3A4 llweakly llat lllow
lldoses
ll

venlafaxine ll(Effexor) ll- llCORRECT llANSWER-treats llboth lldepression lland llanxiety
lldisorders, llensure lltrial llof llhigher lldose llbefore llswitching llto lla lldifferent llmedication

llHalf-life: llParent lldrug ll3-7 llhour; llmetabolite llhas ll9-13 llhour ll

, ll

duloxetine ll(Cymbalta) llSNRI ll- llCORRECT llANSWER-effective llfor llatypical llpain llat
llhigher ll
ll
doses; llappropriate llfor llclients llwho llpresent llwith llsomatic llsymptoms llof
lldepression;
ll
effective llfor llatypical llpain, llsuch llas llfibromyalgia lland lldiabetic
llneuropathy
ll
Half-Life: ll12

llhours
ll
Inhibitor llof

ll2D6
ll

bupropion ll(Wellbutrin) ll- llCORRECT llANSWER-NDRI llmay llimprove llenergy,
llalertness, ll
ll
and llmotivation; llnot llfirst-line lltreatment llfor llanxiety; llcontraindicated llin llclients llwith
lla
ll
history llof

llseizures
ll
Avoid llin llpatients llwith llcomorbid
llanxiety
ll
Half-Life: llParent ll10-14 llhours; llMetabolite ll20-27
llhours
ll
Inhibits
ll2D6
ll

Serotonin llAntagonist lland llReuptake llInhibitors ll(SARIs) ll- llCORRECT llANSWER-SARIs
llpotently llblock ll5-HT2A lland ll5HT ll2C llreceptors, llwhich llallow llmore ll5-HT llto llinteract llat

llpostsynaptic ll5-HT1A llsites. llSerotonin llblockade lland llreuptake llinhibition llis llpresent llat

llhigher lldoses. ll
ll

Trazodone ll- llCORRECT llANSWER-The ll most ll common ll SARI, also
ll ll blocks
llhistaminergic ll
ll
and llα-adrenergic

llreceptors.
ll
Half-Life: ll3-6

llhours
ll

Serotonin llAntagonist lland llReuptake llInhibito
rs ll(SARIs) -ll ll CORRECT llANSWER-Common ll
Adverse llEffectsll
· llsedationll
· lldrowsinessll
· llblurred llvisionll
· llconstipationll
· lldry llmouth ll